Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 Dec;70(830):916–920. doi: 10.1136/pgmj.70.830.916

High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.

P J Van Genderen 1, D N Papatsonis 1, J J Michiels 1, J J Wielenga 1, J Stibbe 1, F J Huikeshoven 1
PMCID: PMC2398043  PMID: 7532860

Abstract

Patients with acquired von Willebrand disease may present with severe bleeding, which is usually difficult to manage. Adequate haemostasis in acquired von Willebrand disease may be achieved with the infusion of factor VIII/von Willebrand factor concentrates or with the administration of desmopressin. We report a case of acquired von Willebrand disease with severe postoperative bleeding, responding poorly to classical von Willebrand factor replacement therapy but successfully treated with high-dose intravenous gammaglobulins. This new treatment mode of acquired von Willebrand disease is discussed in the light of a critical analysis of the literature.

Full text

PDF
916

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Castaman G., Tosetto A., Rodeghiero F. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate. Am J Hematol. 1992 Oct;41(2):132–136. doi: 10.1002/ajh.2830410212. [DOI] [PubMed] [Google Scholar]
  2. Dalton R. G., Dewar M. S., Savidge G. F., Kernoff P. B., Matthews K. B., Greaves M., Preston F. E. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet. 1987 May 2;1(8540):1007–1009. doi: 10.1016/s0140-6736(87)92272-0. [DOI] [PubMed] [Google Scholar]
  3. Delannoy A., Saillez A. C. High-dose intravenous gammaglobulin for acquired von Willebrand's disease. Br J Haematol. 1988 Nov;70(3):387–387. doi: 10.1111/j.1365-2141.1988.tb02502.x. [DOI] [PubMed] [Google Scholar]
  4. Delmer A., Horellou M. H., Bréchot J. M., Prudent J., Potevin F., Lecrubier C., Girard-Longhini C., Samama M., Zittoun R. Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol. 1992 Jun;40(2):151–152. doi: 10.1002/ajh.2830400214. [DOI] [PubMed] [Google Scholar]
  5. Facon T., Caron C., Courtin P., Wurtz A., Deghaye M., Bauters F., Mazurier C., Goudemand J. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. Br J Haematol. 1992 Apr;80(4):488–494. doi: 10.1111/j.1365-2141.1992.tb04562.x. [DOI] [PubMed] [Google Scholar]
  6. Gross S., Traulle C., Capiod J. C., Roussel B., Lafon B., Hayek E., Dieval J., Delobel J. Efficacy of high-dose intravenous gammaglobulin in the management of acquired von Willebrand's disease during orthopaedic surgery. Br J Haematol. 1992 Sep;82(1):170–171. doi: 10.1111/j.1365-2141.1992.tb04610.x. [DOI] [PubMed] [Google Scholar]
  7. Macik B. G., Gabriel D. A., White G. C., 2nd, High K., Roberts H. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med. 1988 Feb;112(2):143–146. [PubMed] [Google Scholar]
  8. Mannucci P. M., Lombardi R., Bader R., Horellou M. H., Finazzi G., Besana C., Conard J., Samama M. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood. 1984 Sep;64(3):614–621. [PubMed] [Google Scholar]
  9. Richard C., Sedano M. C., Cuadrado M. A., Recio M., Hermosa V., Zubizarreta A. Acquired von Willebrand's syndrome associated with hydatid disease of the spleen--disappearance after splenectomy. Thromb Haemost. 1984 Aug 31;52(1):90–93. [PubMed] [Google Scholar]
  10. Ruggeri Z. M., Ware J. The structure and function of von Willebrand factor. Thromb Haemost. 1992 Jun 1;67(6):594–599. [PubMed] [Google Scholar]
  11. Scott J. P., Montgomery R. R. Therapy of von Willebrand disease. Semin Thromb Hemost. 1993;19(1):37–47. doi: 10.1055/s-2007-994004. [DOI] [PubMed] [Google Scholar]
  12. Silberstein L. E., Abrahm J., Shattil S. J. The efficacy of intensive plasma exchange in acquired von Willebrand's disease. Transfusion. 1987 May-Jun;27(3):234–237. doi: 10.1046/j.1537-2995.1987.27387235627.x. [DOI] [PubMed] [Google Scholar]
  13. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  14. Uehlinger J., Rose E., Aledort L. M., Lemer R. Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption. N Engl J Med. 1989 Jan 26;320(4):254–255. doi: 10.1056/NEJM198901263200418. [DOI] [PubMed] [Google Scholar]
  15. White L. A., Chisholm M. Gastro-intestinal bleeding in acquired von Willebrand's disease: efficacy of high-dose immuno-globulin where substitution treatments failed. Br J Haematol. 1993 Jun;84(2):332–334. doi: 10.1111/j.1365-2141.1993.tb03074.x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES